Search

Displaying results 4371 - 4380 of 10000 in total
  1. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  2. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    in a lower risk of off-target effects, including hepatotoxicity. … [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  3. Drug

    Dialyzable leukocyte extract

    go.drugbank.com/drugs/DB16530
    Investigational

    Transferon is comprised of several peptides mixed from human dialyzable leucocyte extracts and acts as an immunomodulator.

  4. Drug

    Raseglurant

    go.drugbank.com/drugs/DB05070
    Investigational

    ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM). … The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD, migraine and anxiety.

  5. Drug

    G17DT Immunogen

    go.drugbank.com/drugs/DB04914
    Investigational

    G17DT Immunogen is a vaccine that neutralizes gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract. … It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine.

    Synonyms: G17DT (AN ANTIGASTRIN IMMUNOGEN)
  6. Drug

    Brodalumab

    go.drugbank.com/drugs/DB11776
    ApprovedInvestigational

    Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.

    Categories: Interleukin-17 Receptor A Antagonist, Interleukin 17 Receptor A Antagonists
  7. Drug

    Palucorcel

    go.drugbank.com/drugs/DB17955
    Investigational

    Palucorcel is an investigational stem cell therapy consisting of human umbilical tissue-derived cells. … Developed by Janssen Biotech, it is being investigated for the treatment of various conditions such as amyotrophic lateral sclerosis (ALS) and macular degeneration.

  8. Drug

    Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase

    go.drugbank.com/drugs/DB18681
    Experimental

    Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase is an investigational lentiviral gene therapy. … It comprises autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that had been genetically modified ex vivo with EFS-ADA LV.

  9. Drug

    Panitumumab

    go.drugbank.com/drugs/DB01269
    ApprovedInvestigational

    Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.

    Products: VECTIBIX 20 MG/ML 20 ML IV INFUZYON ICIN COZELTI ICEREN FLAKON, 1 ADET, VECTIBIX 20 MG/ML 5 ML IV INFUZYON ICIN COZELTI ICEREN FLAKON, 1 ADET
  10. Drug

    Benoxaprofen

    go.drugbank.com/drugs/DB04812
    ApprovedWithdrawn

    The use of benoxaprofen, formerly marketed as Oraflex tablets, was associated with fatal cholestatic jaundice among other serious adverse reactions.

    Synonyms: 2-(p-chlorophenyl)-α-methyl-5-benzoxazoleacetic acid